CISH and neoplasm: The findings were adapted to human iPSC-NK differentiation platform by using CRISPR/Cas9 edited CISH-knockout (CISH−/−) iPSCs and differentiating them into CISH−/− iPSC-NK cells which demonstrate improved metabolic profile, in vivo persistence and increased anti-tumor activity through increased IL-15-mediated JAK-STAT signaling activity (39, 91).